LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.25 5.93

Buy Sell

Overview

Share price change

24h

Current

Min

1.23

Max

1.25

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+206.4% upside

Dividends
By Dow Jones
Next Earnings	3 mar 2026

Market Stats
By TradingEconomics
Market Cap	3.5M 129M
Previous open	-4.68
Previous close	1.25

News Sentiment

By Acuity

50%

127 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 lut 2026, 23:21 UTC

Acquisitions, Mergers, Takeovers

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15 lut 2026, 23:45 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15 lut 2026, 23:40 UTC

Market Talk

Gold Falls on Possible Position Adjustments -- Market Talk

15 lut 2026, 23:06 UTC

Earnings

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15 lut 2026, 23:04 UTC

Earnings

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15 lut 2026, 23:04 UTC

Earnings

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15 lut 2026, 23:01 UTC

Earnings

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15 lut 2026, 23:01 UTC

Earnings

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15 lut 2026, 22:53 UTC

Acquisitions, Mergers, Takeovers

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15 lut 2026, 22:53 UTC

Acquisitions, Mergers, Takeovers

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15 lut 2026, 22:52 UTC

Acquisitions, Mergers, Takeovers

Qube Shareholders to Receive A$5.20/Share in Cash

15 lut 2026, 22:52 UTC

Acquisitions, Mergers, Takeovers

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15 lut 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

BlueScope CEO Tania Archibald Speaking on a Call With Media

15 lut 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15 lut 2026, 22:16 UTC

Acquisitions, Mergers, Takeovers

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15 lut 2026, 22:14 UTC

Acquisitions, Mergers, Takeovers

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15 lut 2026, 22:14 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15 lut 2026, 20:48 UTC

Earnings

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15 lut 2026, 20:47 UTC

Earnings

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15 lut 2026, 20:46 UTC

Earnings

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15 lut 2026, 20:45 UTC

Earnings

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15 lut 2026, 20:44 UTC

Earnings

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15 lut 2026, 20:44 UTC

Earnings

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15 lut 2026, 20:43 UTC

Earnings

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15 lut 2026, 20:42 UTC

Earnings

BlueScope Net Debt A$2.2 Million at Dec. 31

15 lut 2026, 20:42 UTC

Earnings

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15 lut 2026, 20:41 UTC

Earnings

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15 lut 2026, 20:40 UTC

Earnings

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15 lut 2026, 20:40 UTC

Earnings

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15 lut 2026, 20:39 UTC

Earnings

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

206.4% upside

12 Months Forecast

Average 3.83 USD 206.4%

High 7 USD

Low 2 USD

Based on 3 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

127 / 351 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.